Margot J. Pont

Margot J. Pont

Auto-generated profile, based on publicly available information

Margot J. Pont

Fred Hutchinson Cancer Center, Seattle, WA, USA; Galapagos NV, Mechelen, Belgium

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Blood
Verified
Journal Article
Closed access
PDF file
MPMargot J. Pont
Margot J. Pont
THTyler Hill
Tyler Hill
GCGabriel O. Cole
Gabriel O. Cole
JAJoe J. Abbott
Joe J. Abbott
JKJessica Kelliher
Jessica Kelliher
SRStanley R. Riddell
Stanley R. Riddell
B cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase complex, which reduces ligand density on tumor cells for CAR-T cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR-T cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR-T cell recognition of tumor cells, and potentially limit efficacy of BCMA directed adoptive T cell therapy. We investigated whether blocking BCMA cleavage by small molecule γ-secretase inhibitors (GSIs) could augment BCMA-targeted CAR-T cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR-T cells in vitro. GSI treatment of MM tumor bearing NOD/SCID/γc-/- mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR-T cell therapy. Importantly, short term GSI administration to MM patients markedly increases the percentage of BCMA+tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, an FDA-approved clinical trial (NCT03502577) has been initiated, combining GSI with concurrent BCMA CAR-T cell therapy. Key Points Small molecule γ-secretase inhibitors increase BCMA surface expression on myeloma cells, resulting in enhanced CAR-T cell efficacy.

24 November 2022 in Blood
Verified
Journal Article
Open access
PDF file
AWAlec B. Wilkens
Alec B. Wilkens
EFElena C. Fulton
Elena C. Fulton
MPMargot J. Pont
Margot J. Pont
GCGabriel O. Cole
Gabriel O. Cole
ILIsabel Leung
Isabel Leung
SRStanley R. Riddell
Stanley R. Riddell
Adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T) effectively treats refractory hematologic malignancies in a subset of patients but can be limited by poor T-cell expansion and persistence in vivo. Less differentiated T-cell states correlate with the capacity of CAR-T to proliferate and mediate antitumor responses, and interventions that limit tumor-specific T-cell differentiation during ex vivo manufacturing enhance efficacy. NOTCH signaling is involved in fate decisions across diverse cell lineages and in memory CD8+ T cells was reported to upregulate the transcription factor FOXM1, attenuate differentiation, and enhance proliferation and antitumor efficacy in vivo. Here, we used a cell-free culture system to provide an agonistic NOTCH1 signal during naïve CD4+ T-cell activation and CAR-T production and studied the effects on differentiation, transcription factor expression, cytokine production, and responses to tumor. NOTCH1 agonism efficiently induced a stem cell memory phenotype in CAR-T derived from naïve but not memory CD4+ T cells and upregulated expression of AhR and c-MAF, driving heightened production of interleukin-22, interleukin-10, and granzyme B. NOTCH1-agonized CD4+ CAR-T demonstrated enhanced antigen responsiveness and proliferated to strikingly higher frequencies in mice bearing human lymphoma xenografts. NOTCH1-agonized CD4+ CAR-T also provided superior help to cotransferred CD8+ CAR-T, driving improved expansion and curative antitumor responses in vivo at low CAR-T doses. Our data expand the mechanisms by which NOTCH can shape CD4+ T-cell behavior and demonstrate that activating NOTCH1 signaling during genetic modification ex vivo is a potential strategy for enhancing the function of T cells engineered with tumor-targeting receptors.

12 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPM J Pont
M J Pont
MHM W Honders
M W Honders
AKA N Kremer
A N Kremer
CKC van Kooten
C van Kooten
COC Out
C Out
MGMarieke Griffioen
Marieke Griffioen
Cellular immunotherapy has proven to be effective in the treatment of hematological cancers by donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation and more recently by targeted therapy with chimeric antigen or T-cell receptor-engineered T cells. However, dependent on the tissue distribution of the antigens that are targeted, anti-tumor responses can be accompanied by undesired side effects. Therefore, detailed tissue distribution analysis is essential to estimate potential efficacy and toxicity of candidate targets for immunotherapy of hematological malignancies. We performed microarray gene expression analysis of hematological malignancies of different origins, healthy hematopoietic cells and various non-hematopoietic cell types from organs that are often targeted in detrimental immune responses after allogeneic stem cell transplantation leading to graft-versus-host disease. Non-hematopoietic cells were also cultured in the presence of IFN-γ to analyze gene expression under inflammatory circumstances. Gene expression was investigated by Illumina HT12.0 microarrays and quality control analysis was performed to confirm the cell-type origin and exclude contamination of non-hematopoietic cell samples with peripheral blood cells. Microarray data were validated by quantitative RT-PCR showing strong correlations between both platforms. Detailed gene expression profiles were generated for various minor histocompatibility antigens and B-cell surface antigens to illustrate the value of the microarray dataset to estimate efficacy and toxicity of candidate targets for immunotherapy. In conclusion, our microarray database provides a relevant platform to analyze and select candidate antigens with hematopoietic (lineage)-restricted expression as potential targets for immunotherapy of hematological cancers.

9 September 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
APAndrew Jay Portuguese
Andrew Jay Portuguese
STSherilyn A. Tuazon
Sherilyn A. Tuazon
MPMargot J. Pont
Margot J. Pont
GCGabriel O. Cole
Gabriel O. Cole
BSBlythe D. Sather
Blythe D. Sather
ACAndrew J. Cowan
Andrew J. Cowan

1 March 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SJSrirama Josyula
Srirama Josyula
MPMargot J. Pont
Margot J. Pont
JKJacob Keane-Candib
Jacob Keane-Candib
XSXiaoling Song
Xiaoling Song
STSushma Thomas
Sushma Thomas
JHJoshua aiden Hill
Joshua aiden Hill

3 April 2023
Verified
Other
Open access
MPMargot J. Pont
Margot J. Pont
RORimke Oostvogels
Rimke Oostvogels
CBCornelis A.M. Van Bergen
Cornelis A.M. Van Bergen
EMEdith D. van der Meijden
Edith D. van der Meijden
MHMaria W. Honders
Maria W. Honders
RSRobbert M. Spaapen
Robbert M. Spaapen